Quantumzyme Clears OTC Markets Caveat Emptor Designation, Enhancing Investor Confidence

Quantumzyme Corp. (OTC: QTZM), a biotechnology firm specializing in computational enzyme engineering, has announced the removal of the 'Caveat Emptor' designation by OTC Markets Group. This development signifies the company's transition to a Current Information issuer with a Verified Profile, showcasing its adherence to the OTCID disclosure framework. The removal comes after Quantumzyme's concerted efforts to enhance its disclosure practices, including the submission of updated financial reports, identity verification, and measures to improve corporate transparency.

The company's CEO, Naveen Kulkarni, expressed satisfaction with the lifting of the Caveat Emptor warning, emphasizing Quantumzyme's dedication to transparency, compliance, and market integrity. This milestone allows the company to refocus on its business strategy and the creation of long-term shareholder value, reinforcing its commitment to high standards of corporate governance.

Quantumzyme has also clarified its stance against unauthorized promotional activities, specifically those that occurred in March 2025, stating its full cooperation with related inquiries. The company's proactive approach in addressing these issues has been pivotal in restoring its standing with investors and the broader market.

For further details on Quantumzyme's progress and updates, interested parties can visit the company's website at https://www.quantumzymecorp.com or its profile on OTC Markets at https://www.otcmarkets.com/stock/QTZM.